Under the terms of a settlement and license agreement with Regeneron, Samsung Bioepis will be able to launch Opuviz in the U.S. in January 2027, according to a press release.
“As with ranibizumab biosimilars, aflibercept biosimilars have the potential to significantly improve accessibility and affordability for patients,” Thomas Newcomer, vice president and head of U.S. commercial operations at Samsung Bioepis, told Healio. “As demand for treatment continues to grow, biosimilars can help manage costs with confidence without compromising on clinical standards.”
Opuviz (aflibercept-yszy 2 mg,